BioMarin Files Vosoritide For Achondroplasia, But Investors Still Upset About Gene Therapy Setback

 
• By Jessica Merrill

Vosoritide, a once daily injection, could be the first drug available for achondroplasia, the most common form of dwarfism.

Milestone - white wooden signpost with one arrow
BioMarin met one of two big milestones for the second half of the year • Source: Shutterstock

More from New Products

More from Scrip